Page last updated: 2024-12-05

3,4-dichloro-1-butene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3,4-dichloro-1-butene: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID12971
CHEMBL ID3182884
SCHEMBL ID190697
MeSH IDM0134071

Synonyms (40)

Synonym
ia19eyw12d ,
ccris 8555
ec 212-079-0
4-01-00-00772 (beilstein handbook reference)
unii-ia19eyw12d
1-butene, 3,4-dichloro-
1,2-dichloro-3-butene
3,4-dichlorobut-1-ene
3,4-dichloro-1-butene
3,4-dichlorobutene-1
1-butene, 3,4-dichloro-, (+-)-
brn 1739135
hsdb 5751
einecs 212-079-0
760-23-6
inchi=1/c4h6cl2/c1-2-4(6)3-5/h2,4h,1,3h
3,4-dichloro-1-butene, 98%
D1072
NCGC00249032-01
NCGC00256397-01
dtxsid8022113 ,
cas-760-23-6
dtxcid902113
tox21_302814
tox21_201361
NCGC00258913-01
AKOS006220765
FT-0614245
SCHEMBL190697
1-butene, 3,4-dichloro-, (+/-)-
3,4-dichlorobut-1-ene [hsdb]
1,2-dichlorobut-3-ene
CHEMBL3182884
mfcd00000947
2-undecynoicacidmethylester
3,4-dichloro-1 -butene
Q27280624
D89774
BS-23013
EN300-7426254

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"In dose-response analysis, regression analysis and hypothesis testing are the main tools of choice."( Reconsidering sufficient and optimal test design in acute toxicity testing.
Jager, T, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency22.27713.189029.884159.4836AID1224846
AR proteinHomo sapiens (human)Potency28.46200.000221.22318,912.5098AID743035; AID743063
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency35.00650.003041.611522,387.1992AID1159552; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency13.93630.001530.607315,848.9004AID1224841
pregnane X nuclear receptorHomo sapiens (human)Potency31.35590.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency22.11120.000229.305416,493.5996AID743069; AID743075
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency63.09570.001019.414170.9645AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency0.70790.023723.228263.5986AID743223
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (33.33)18.7374
1990's1 (16.67)18.2507
2000's1 (16.67)29.6817
2010's1 (16.67)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.95 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]